BiotechTube
Arthro Kinetics

Arthro Kinetics

Vienna, Austria· Est.
arthro-kinetics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $8M

Overview

Arthro Kinetics is a private, pre-revenue biotech focused on advanced autologous cell therapies for orthopedic tissue repair. Its proprietary platform centers on a 3D collagen type I matrix designed to enhance the cultivation and implantation of a patient's own cells to restore natural tissue function. The company is positioned in the growing regenerative medicine market, targeting significant unmet needs in cartilage damage and osteoarthritis. Its development stage is likely pre-clinical or early clinical, given the nature of its technology and the typical timeline for such therapies.

OrthopedicsCartilage Repair

Technology Platform

Proprietary 3D collagen type I matrix for the cultivation and implantation of autologous cells in tissue regeneration.

Funding History

1
Total raised:$8M
Series A$8M

Opportunities

The large and growing global market for cartilage repair and osteoarthritis treatments presents a significant opportunity.
The shift towards regenerative medicine and personalized therapies aligns perfectly with the company's autologous, cell-based platform.
The 3D matrix technology could also have applications beyond therapeutics, such as in drug testing and other tissue engineering fields.

Risk Factors

Major risks include the high technical and clinical hurdles of regenerating functional cartilage, the complex and costly regulatory pathway for advanced therapy products, and challenges in scaling and commercializing an autologous, personalized therapy.
Competition from both established surgical techniques and newer allogeneic cell therapies is also a key risk.

Competitive Landscape

Arthro Kinetics competes in the cartilage repair segment with companies offering cell-based therapies like Vericel (MACI), traditional surgical techniques, and allogeneic cell therapy developers. Its differentiation lies in its specific 3D collagen matrix designed to optimize autologous cell growth and implantation. It faces competition from larger medtech firms with significant commercial reach in orthopedics.

More companies in Biologics / Biosimilars →More companies in Austria →